6.08

2.72% -0.17

After Hours: 6.09 0.010 +0.16%

Unicycive Therapeutics Inc (UNCY)

Overview News Price History Financials Discussions Forecast

Unicycive Therapeutics Inc stock is traded at $6.08, with a volume of 305.47K. It is down -2.72% in the last 24 hours and up +3.58% over the past month. Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Previous Close:

$6.25

Open:

$6.28

24h Volume:

305.47K

Relative Volume:

0.61

Market Cap:

$130.67M

Revenue:

Net Income/Loss:

$-30.54M

P/E Ratio:

-3.9226

EPS:

-1.55

Net Cash Flow:

$-18.30M

1W Performance:

-1.78%

1M Performance:

+3.58%

6M Performance:

+43.06%

1Y Performance:

+1,044%

1-Day Range:

$5.98

$6.28

1-Week Range:

$5.98

$6.78

52-Week Range:

$0.45

$8.2457

Unicycive Therapeutics Inc Stock (UNCY) Company Profile

Name

Unicycive Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

650-384-0642

Address

4300 EL CAMINO REAL, SUITE 210, LOS ALTOS

Employee

Twitter

Next Earnings Date

2025-03-31

Latest SEC Filings

UNCY's Discussions on Twitter

Compare UNCY vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
UNCY Unicycive Therapeutics Inc	6.08	134.32M	0	-30.54M	-18.30M	-1.55
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-25	Initiated	Guggenheim	Buy
Apr-04-24	Initiated	Piper Sandler	Overweight

Unicycive Therapeutics Inc Stock (UNCY) Latest News

11:00 AM

2026-02-12 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Reach Out | NDAQ:UNCY | Press Release - Stockhouse

11:00 AM

Feb 06, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Feb 06, 2026

Feb 04, 2026

Investor Mood: Is Open Lending Corporation stock a top performer YTDWatch List & Technical Buy Zone Confirmations - baoquankhu1.vn

Feb 04, 2026

Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit - The Manila Times

Feb 04, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Investors to Inquire about Securities Investigation - ACCESS Newswire

Feb 04, 2026

Feb 03, 2026

Unicycive Therapeutics Doubles Stock Sale Agreement - MSN

Feb 03, 2026

Jan 31, 2026

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Phibro Animal Health (PAHC) and Unicycive Therapeutics (UNCY) - The Globe and Mail

Jan 31, 2026

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Unicycive Therapeutics (UNCY) - The Globe and Mail

Jan 31, 2026

Jan 30, 2026

Unicycive’s Kidney Drug Pipeline Puts A Small Stock On The Clock - Finimize

Jan 30, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Jan 30, 2026

Jan 29, 2026

Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile - Seeking Alpha

Jan 29, 2026

Take two: Company tries again to win FDA approval for drug for dialysis patients - The Business Journals

Jan 29, 2026

Unicycive Therapeutics announces FDA acceptance of oxylanthanum carbonate (OLC) new drug application (NDA) resubmission - marketscreener.com

Jan 29, 2026

UPDATEUnicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - The Manila Times

Jan 29, 2026

Unicycive Therapeutics Announces FDA Acceptance Of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - TradingView

Jan 29, 2026

Unicycive granted FDA review for resubmitted marketing application for kidney disease drug - Seeking Alpha

Jan 29, 2026

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - The Manila Times

Jan 29, 2026

FDA sets June 27 action date for Unicycive kidney disease pill - stocktitan.net

Jan 29, 2026

Jan 28, 2026

FY2030 Earnings Forecast for UNCY Issued By HC Wainwright - Defense World

Jan 28, 2026

Jan 27, 2026